CD28 and cancer: CD86 (B7-2), one of the checkpoint proteins in antigen-presenting cells (APCs), interacts with CD28 and cytotoxic T lymphocyte antigen‐4 (CTLA‐4) receptors on T cells, thereby limiting T-cell activation and inducing immunoescape of cancers (42, 43).